Loading…
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $634M | $54M | $-27M | $30M | -9.9% | 20.0% | - |
| 2024 | $528M | $29M | $-56M | $-37M | -28.9% | 32.3% | - |
| 2023 | $399M | $-92M | $-152M | $-77M | -94.6% | 21.3% | - |
| 2022 | $329M | $-200M | $-237M | $-170M | -192.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 329.23 | 399.36 | 528.29 | 634.21 |
| Cost Of Revenue | 38.60 | 37.33 | 52.94 | 72.93 |
| Gross Profit | 290.63 | 362.03 | 475.35 | 561.28 |
| Operating Expense | 495.06 | 435.52 | 441.29 | 526.79 |
| Operating Income | -204.43 | -73.49 | 34.06 | 34.49 |
| EBITDA | -199.58 | -92.08 | 29.39 | 53.81 |
| EBIT | -204.92 | -99.95 | 20.84 | 46.35 |
| Pretax Income | -242.04 | -150.10 | -28.76 | 0.19 |
| Tax Provision | -5.47 | 1.48 | 27.35 | 27.30 |
| Net Income | -236.57 | -151.58 | -56.11 | -27.11 |
| Net Income Common Stockholders | -236.57 | -151.58 | -56.11 | -27.11 |
| Total Expenses | 533.66 | 472.85 | 494.23 | 599.72 |
| Interest Expense | 37.12 | 50.15 | 49.60 | 46.16 |
| Interest Income | 3.02 | 7.08 | 5.41 | 3.32 |
| Research And Development | 276.68 | 152.38 | 109.36 | 135.84 |
| Selling General And Administration | 213.04 | 275.27 | 323.38 | 383.49 |
| Normalized EBITDA | -191.88 | -74.43 | 38.58 | 55.51 |
| Normalized Income | -229.03 | -137.64 | -48.85 | -25.77 |
| Basic EPS | -0.82 | -0.51 | -0.18 | 0 |
| Diluted EPS | -0.82 | -0.51 | -0.18 | 0 |
| Tax Effect Of Unusual Items | -0.15 | -3.71 | -1.93 | -0.36 |
| Tax Rate For Calcs | 0.02 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | -7.69 | -17.65 | -9.19 | -1.70 |
| Total Unusual Items Excluding Goodwill | -7.69 | -17.65 | -9.19 | -1.70 |
| Net Income From Continuing Operation Net Minority Interest | -236.57 | -151.58 | -56.11 | -27.11 |
| Reconciled Depreciation | 5.34 | 7.87 | 8.55 | 7.46 |
| Reconciled Cost Of Revenue | 38.60 | 37.33 | 52.94 | 72.93 |
| Net Interest Income | -34.09 | -43.07 | -44.19 | -42.84 |
| Net Income From Continuing And Discontinued Operation | -236.57 | -151.58 | -56.11 | -27.11 |
| Total Operating Income As Reported | -212.12 | -77.21 | 24.88 | 32.79 |
| Diluted Average Shares | 289.06 | 295.16 | 304.38 | 0 |
| Basic Average Shares | 289.06 | 295.16 | 304.38 | 0 |
| Diluted NI Availto Com Stockholders | -236.57 | -151.58 | -56.11 | -27.11 |
| Net Income Including Noncontrolling Interests | -236.57 | -151.58 | -56.11 | -27.11 |
| Net Income Continuous Operations | -236.57 | -151.58 | -56.11 | -27.11 |
| Other Income Expense | -3.52 | -33.54 | -18.63 | 8.54 |
| Other Non Operating Income Expenses | 4.18 | -15.89 | -9.44 | 10.24 |
| Special Income Charges | -7.69 | -17.65 | -9.19 | -1.70 |
| Other Special Charges | 0 | 13.93 | 0 | 0 |
| Write Off | 6.62 | 1.13 | 0 | 1.70 |
| Restructuring And Mergern Acquisition | 1.08 | 2.58 | 9.19 | 0 |
| Net Non Operating Interest Income Expense | -34.09 | -43.07 | -44.19 | -42.84 |
| Interest Expense Non Operating | 37.12 | 50.15 | 49.60 | 46.16 |
| Interest Income Non Operating | 3.02 | 7.08 | 5.41 | 3.32 |
| Depreciation Amortization Depletion Income Statement | 5.34 | 7.87 | 8.55 | 7.46 |
| Depreciation And Amortization In Income Statement | 5.34 | 7.87 | 8.55 | 7.46 |
| Operating Revenue | 329.23 | 399.36 | 528.29 | 634.21 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc.this co. | FOLD | $4.5B | - | 16.43 | -9.9% | 112.00 |
| Lantheus Holdings, Inc. | LNTH | $5.3B | 23.80 | 4.81 | 21.4% | 14.41 |
| PACS Group, Inc. | PACS | $5.2B | 27.38 | 5.53 | 20.1% | 23.70 |
| CRISPR Therapeutics AG | CRSP | $4.9B | - | 2.53 | -30.3% | -5.64 |
| Dianthus Therapeutics, Inc. | DNTH | $4.5B |
| - |
| 7.31 |
| -32.9% |
| -18.62 |
| Alignment Healthcare, Inc. | ALHC | $4.5B | - | 24.74 | -0.4% | 90.31 |
| Option Care Health, Inc. | OPCH | $4.2B | 21.16 | 3.18 | 15.7% | 12.82 |
| Crinetics Pharmaceuticals, Inc. | CRNX | $4.0B | - | 3.70 | -46.9% | -5.94 |
| iRhythm Holdings, Inc. | IRTC | $4.0B | - | 25.53 | -29.2% | -132.48 |
| Peer Median | - | 23.80 | 5.17 | -14.8% | 3.59 | |